Elevated ERK1/2 activity has been found in inflamed joints of patients with the autoimmune disease rheumatoid arthritis (RA) [95] and ERK1/2 inhibitors show therapeutic promise by reducing levels of RA-associated inflammatory cytokines including TNF, IL-1 and IL-6 [96]. Here, IL6 is linked to rheumatoid arthritis.